One of the largest US clinical laboratory testing companies, offering diagnostic testing and drug-development (CRO) services.
One of the largest US clinical laboratory testing companies, offering diagnostic testing and drug-development (CRO) services.
The diagnostics side is paid per test by insurers and government programs, and hospital outreach-lab acquisitions have been a main route of growth. The drug-development side charges drugmakers fees per study, so revenue follows pharma outsourcing. In 2023 it spun off its clinical-trial management arm as Fortrea, keeping the lab-testing side.
Moat: narrow (scale, distribution, installed base). National lab/patient-service-center network and payer contracts create scale advantages over smaller labs.
Headquarters: Burlington, North Carolina, USA · Founded: 1971 · Employees: 71,000
Size Labcorp (LH) is a United States Health Care company (Medical/Nursing Services) with a market value of $30.1B, the 366th largest of 3,085 United States companies the cockpit tracks. Shares closed at $370.78 on 18 Nov 2026.
Performance Over six months the shares gained 44.4%, against +8.5% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 9 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +5.6%); the operating margin is 11.3% (peer median 10.4%).
Valuation It trades at 19.3× forward earnings against a peer median of 18.3× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points below its cost of capital (8.7% WACC).
Credit Labcorp has 6 bonds outstanding ($3.75B), rated BBB by the agencies and trading like A at a weighted spread of 78 bp.
Short interest Short interest is 3.1% of the free float (30 Oct 2026).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $14.6B | $14.0B | $13.0B | $12.2B | $11.9B |
| Revenue growth | — | +7% | +7% | +3% | — |
| Gross profit | $3.92B | $3.73B | $3.37B | $3.15B | $3.52B |
| EBITDA | $2.35B | $2.48B | $2.04B | $1.70B | $2.29B |
| Net income | $1.00B | $876M | $746M | $418M | $1.28B |
| Free cash flow | $1.29B | $1.21B | $1.10B | $874M | $1.53B |
| Capital expenditure | $528M | $434M | $490M | $454M | $429M |
| Total debt | $6.78B | $6.53B | $7.27B | $5.95B | $6.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Labcorp LH | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% |
| Quest Diagnostics DGX | $28.6B | +34% | +9% | 15% | 22.4× | 7.2% |
| ICON ICLR | $14.6B | +70% | +1% | 10% | 17.3× | 15.9% |
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.8% | +6.7% | 2nd highest of 9 |
| 6-month return | +44.4% | +8.5% | highest of 9 |
| Distance from 52-week high | -1.1% | -12.1% | highest of 9 |
| Revenue growth (TTM) | +6.0% | +5.6% | 5th highest of 9 |
| Operating margin | 11.3% | 10.4% | 4th highest of 9 |
| Forward P/E | 19.3× | 18.3× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 14.5% | 5.9% | 2nd most demanding of 8 |
| Growth delivered (Del g) | 0.0% | +5.0% | lowest of 8 |
| Hurdle (Req g minus delivered) | +14.5 pp | -1.6 pp | most demanding of 8 |
| ROIC minus cost of capital | -0.2 pp | +1.0 pp | 3rd lowest of 9 |
| EV / EBITDA | 15.6× | 11.0× | 3rd most expensive of 7 |
| Net debt / EBITDA | 2.8× | 2.7× | 4th most indebted of 8 |
| Bond spread | 78 bp | 107 bp | tightest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Labcorp LH | United States | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% | 0.0% |
| Koninklijke Philips PHIA.AS | Netherlands | $29.0B | +17% | -1% | 10% | 16.4× | 5.9% | +0.6% |
| Solventum SOLV | United States | $14.7B | +14% | -3% | 8% | 11.7× | n/a | n/a |
| BrightSpring Health Services BTSG | United States | $13.6B | +17% | +23% | 4% | 28.8× | 24.9% | +18.3% |
| Encompass Health EHC | United States | $13.2B | +27% | +9% | 18% | 20.1× | 5.7% | +5.0% |
| Aier Eye Hospital 300015.SZ | China | $12.5B | -14% | +5% | 21% | 30.1× | 11.8% | +13.4% |
| Fresenius Medical Care FME.DE | Germany | $11.2B | +3% | -1% | 11% | 9.5× | -4.8% | +1.9% |
| Ensign ENSG | United States | $10.7B | +3% | +17% | 9% | 21.3× | 12.7% | +16.5% |
| DaVita DVA | United States | $10.2B | -18% | +6% | 15% | 10.1× | -2.5% | +3.4% |
Labcorp has 6 bonds outstanding with $3.75B face value. The agencies rate it BBB; its bonds trade like A. Weighted yield 5.48%, a spread of 78 bp over government bonds.